Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | SMO | Q99835 | 1/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2975725 | 0.85 | DRD2 (0.36) | P2RX7HPGDDRD2DRD4RIPK2 | |
| SCHEMBL13097289 | 0.78 | DRD2 (0.32) | P2RX7DRD2DRD4RIPK2LMNA | |
| SCHEMBL13097286 | 0.77 | DRD2 (0.32) | P2RX7DRD2DRD4RIPK2LMNA | |
| SCHEMBL13097351 | 0.77 | DRD2 (0.39) | P2RX7HPGDDRD2DRD4RIPK2 | |
| SCHEMBL13097216 | 0.77 | RIPK2 (0.33) | P2RX7ANO1RIPK2 | |
| SCHEMBL13097332 | 0.76 | P2RX7 (0.38) | P2RX7HPGDDRD2DRD4CYP3A4 | |
| SCHEMBL13097299 | 0.69 | SLC22A12 (0.33) | RIPK2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL13097295 | 0.69 | LMNA (0.32) | P2RX7DRD2DRD4RIPK2CYP3A4 | |
| SCHEMBL12748445 | 0.68 | CTSL (0.37) | ANO1PTGER4CNR2LMNA | |
| SCHEMBL811961 | 0.68 | WNT3A (0.43) | CNR2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267964-A1 | N-HETEROCYCLYLPHENYL-SUBSTITUTED CYCLIC KETOENOLS | FISCHER REINER | 2010-10-21 | — | — | US | disclosed |
| US-7776791-B2 | N-heterocyclyl phenyl-substituted cyclic ketoenols | BAYER CROPSCIENCE AG (DE) | 2010-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267964-A1 | N-HETEROCYCLYLPHENYL-SUBSTITUTED CYCLIC KETOENOLS | CYP17A1, CCNY, CCNE2 | P2RX7 2789/4885HPGD 116/4885ANO1 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.